Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103037 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01103037 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT01103037, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
Interventions
- DRUG QAV680
- DRUG QAV680 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103037
The ClinicalTrials.gov registry entry for NCT01103037 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QAV680 is the first listed.
NCT01103037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103037 about?
NCT01103037 is a clinical study titled "Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma". This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
What is the current status of trial NCT01103037?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2010-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01103037?
The interventions under investigation include: QAV680 (DRUG), QAV680 Placebo (DRUG).
Who is sponsoring clinical trial NCT01103037?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.